Stocktoria
Medtronic plc MDT
Medtronic plc (MDT) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 3.51% (safety: stretched). FY2026 revenue was $36.4B at a 13.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.58 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-28 | UBS | Buy (up) |
| 2026-07-10 | TD Cowen | Buy (main) |
| 2026-07-06 | Evercore ISI Group | Outperform (main) |
| 2026-06-17 | Needham | Buy (reit) |
| 2026-06-05 | Goldman Sachs | Neutral (main) |
| 2026-06-05 | Bernstein | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.141 |
| Retained earnings / assets | 0.351 |
| EBIT / assets | 0.07 |
| Equity / liabilities | 1.166 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MDT | Medtronic plc | 7/9 | 3.76 | 21.6 | +8.4% |
| ITGR | Integer Holdings Corp | 6/9 | 3.52 | 31 | +8% |
| MASI | MASIMO CORP | 7/9 | 6.71 | — | +9.4% |
| LIVN | LivaNova PLC | 4/9 | 0.72 | — | +10.7% |
| CNMD | CONMED Corp | 5/9 | 2.97 | 23 | +5.2% |
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
| AXGN | Axogen, Inc. | 5/9 | -0.43 | — | +20.2% |
About Medtronic plc
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
FAQ
Is MDT financially healthy?
Medtronic plc's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does MDT pay a dividend, and is it safe?
Yes. Medtronic plc pays a dividend yielding about 3.51% with a 75.8% payout ratio, rated “stretched” for safety.
How profitable is MDT?
In FY2026, Medtronic plc had a net margin of 13.2% and a return on equity of 9.6%.
Is MDT overvalued or undervalued?
Medtronic plc trades at about 24.3× trailing earnings — below its 10-year norm (10-year range 19.8×–47.6×, median 29.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for MDT?
The average Wall-Street price target for Medtronic plc is $98.44, about 8.5% above the recent price, from 25 analysts (consensus: buy).
Is MDT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Medtronic plc: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 21.6×, a dividend yield of 3.51%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-04-24. Facts plus Stocktoria's own computed scores — not investment advice.